Search Results

You are looking at 1 - 10 of 494 items for :

  • "adverse events" x
Clear All
Full access

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins and Michael J. Sorich

associated with significant adverse events (AEs), including death. 2 In contrast to other anticancer therapies, ICIs cause heterogeneous toxicities through nonspecific immune activation affecting tissues and organs. Although guidelines exist for the diagnosis

Full access

Jarushka Naidoo, Jiajia Zhang, Evan J. Lipson, Patrick M. Forde, Karthik Suresh, Kendall F. Moseley, Seema Mehta, Shawn G. Kwatra, Alyssa M. Parian, Amy K. Kim, John C. Probasco, Rosanne Rouf, Jennifer E. Thorne, Satish Shanbhag, Joanne Riemer, Ami A. Shah, Drew M. Pardoll, Clifton O. Bingham III, Julie R. Brahmer and Laura C. Cappelli

immune-related toxicities require multidisciplinary management. Due to their mechanism of action, immune checkpoint inhibitors (ICIs) can cause patients to develop a variety of organ-specific immune-related adverse events (irAEs). 7 Similarly, patients

Full access

Caroline C. Henson, Carmel N. Anandadas, Lisa H. Barraclough, Ric Swindell, Catharine M.L. West and Susan E. Davidson

The NCI’s Common Terminology Criteria for Adverse Events (CTCAE) is the preferred method for capturing adverse events in clinical trials. 1 CTCAE was the first system for recording acute and late treatment effects that was suitable for use with

Full access

Cynthia L. Gong and Joel W. Hay

. Adverse event probabilities were derived from the clinical trials. Only adverse events significantly different from prednisone or unique because of the mechanism of action were included in the model ( Table 2 ). All adverse events included were those rated

Full access

Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad and Andrea Wahner Hendrickson

homologous recombination. Clinical trials in breast and ovarian cancers have led to several FDA approvals in recent years, and their use in clinical practice is continuing to rise. It is thus necessary to assess their adverse event (AE) profile. Method

Full access

Meily Arevalo, Myo H. Zaw, Anita Sultan, Sriman Swarup, Nay N. Yee, Wai L. Thein, Myet M. Zin, Nusrat Jahan and Kyaw Z. Thein

due to adverse events. Methods: We performed a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts through September 2018. Phase 3 RCTs that mention gastrointestinal toxicities and the rate of treatment

Full access

Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque and David G. Pfister

Adverse events were graded according to the NCI Common Terminology Criteria for Adverse Events, version 3.0. Physical examination with assessment of adverse events was required at the start of each 4-week cycle. Toxicity management guidelines included dose

Full access

Narendranath Epperla, Melissa Pavilack, Temitope Olufade, Richa Bashyal, Teng Huang, Huseyin Yuce and Leslie Andritsos

Background: Purine nucleoside analogs (PNAs) are highly effective for first-line treatment of hairy cell leukemia (HCL). In clinical trials of single PNAs, several adverse events (AEs) were reported; however, little is known regarding the costs and

Full access

Antonio Palumbo and Roberto Mina

toxicities; thus, appropriate and prompt management of treatment-related adverse events is needed ( Table 1 ). Transplant-Ineligible Patients Patients older than 65 years are usually not considered eligible for high-dose therapy followed by ASCT

Full access

Tarek Haykal, Babikir Kheiri, Varun Samji, Yazan Zayed, Ragheed Al-Dulaimi, Inderdeep Gakhal, Areeg Bala, Jason Sotzen, Ahmed Abdalla and Ghassan Bachuwa

metastatic RCC. Despite the proven efficacy of sunitinib, prolonged treatment with some tyrosine kinase inhibitors (TKIs) has been associated with significant adverse events (AEs). Therefore, we aimed to calculate the exact prevalence of all sunitinib